796034-18-9

Upstream product

• 796034-16-7 2-benzyl-3-[4-(4,4,5,5-tetramethyl-[1,3,2]-dioxoborolan-2-yl)phenyl]-benzofuran 
• 85060-86-2 2,2-dimethyl-5-(p-bromophenacyl)-1,3-dioxane-4,6-dione 

Downstream Products

• 796739-04-3 4-[4'-(2-benzylbenzofuran-3-yl)biphenyl-4-yl]-4-oxobutyric acid 
• 796034-19-0 5-benzyl-5-{2-[4'-(2-benzylbenzofuran-3-yl)-biphenyl-4-yl]-2-oxoethyl}-2,2-dimethyl-[1,3]-dioxane-4,6-dione 

Relevant academic research and scientific papers

PHENYL SUBSTITUTED CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

Substituted carboxylic acids

The present invention relates to compounds and pharmaceutically acceptable salts of formula I: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine

SUBSTITUTED CARBOXYLIC ACIDS

The present invention relates to compounds and pharmaceutically acceptable salts of formula (I) : which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosi

PHENYL SUBSTITUTED CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.